Related Experiment Video
Updated: Mar 12, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Improving Pre-Exposure Prophylaxis Adherence in People at Risk for HIV: Secondary Analysis of a Digital Health
Lisa Hightow-Weidman1, Seul-Ki Choi2, Ibrahim Yigit1
1Institute on Digital Health and Innovation, College of Nursing, Florida State University, Innovation Park, Research Building B, 2010 Levy Avenue, RM B3400, Tallahassee, FL, 32310, United States, 1 9199499540.
Background:
Although highly effective HIV pre-exposure prophylaxis (PrEP) is available, its usage and adherence among young men who have sex with men and young transgender women remain low, reducing its overall effectiveness. The study included a 3-arm randomized clinical trial of Prepared, Protected, emPowered (P3), a comprehensive PrEP adherence digital health intervention, compared to an enhanced version, P3+, which incorporates in-app adherence coaching.
Objective:
This study aims to analyze data from study participants in the P3/P3+ intervention arms to understand how different levels of user engagement with the app's features were associated with adherence to PrEP as well as the costs of each intervention and their relative cost-effectiveness.
Methods:
Descriptive statistics for study variables at baseline were calculated. To examine the differences in intervention engagement and acceptability by arm, independent samples 2-tailed t tests for continuous variables and a chi-square analysis for categorical variables were conducted. To examine the effect of arm and engagement categories on PrEP adherence at 3 months, three logistic regression analyses were conducted: (1) the effect of arm on PrEP adherence, (2) the effect of predefined engagement categories (high vs moderate and low) on PrEP adherence, and (3) the interaction effect of arm and predefined engagement categories on PrEP adherence, along with the main effects of arm and predefined engagement categories. The study team calculated the average cost per participant and the incremental cost-effectiveness for PrEP adherence and engagement measures.
Results:
A total of 163 participants were randomized to the P3 intervention (82 to the P3 arm and 81 to the P3+ arm). Participants in the P3+ arm earned higher incentives (US $90.6 vs $75.4; P=.04), had more app log-ins (96.6 vs 76.1; P=.01), used the app on more days (63.3 d vs 53.2 d; P=.04), and spent more time in the intervention (378.8 min vs 186.66 min; P<.001) compared to those in the P3 arm. There was no significant association between intervention arm and PrEP adherence at 3 months (P=.99). Engagement category (high vs moderate or low) was significantly associated with PrEP adherence at 3 months (P=.003). The overall average total monthly cost of P3 was US $1118 (SD $305.1). Average total monthly cost per P3 participant was $280 (SD $118.5), with an additional cost for P3+ of $72.
Conclusions:
This study highlights the critical role of user engagement in enhancing PrEP adherence among young individuals at high risk for HIV. While the P3+ intervention led to increased engagement, this did not translate into significantly better adherence compared to the standard P3 arm. This, coupled with the increased cost and complexity of P3+ delivery, indicates that further studies are necessary to determine whether this intensified intervention is the appropriate fit.
Related Concept Videos
Retrovirus Life Cycles
Sexually Transmitted Infections
Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...

